Evidence map›Paper›PMID 32203160›Full record

ArticleOncogene2020

NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21

Mark Williams, Xinhui Liu, Yueqi Zhang, Jake Reske, Devika Bahal, Trevor G Gohl, Daniel Hollern, Elliot Ensink, Matti Kiupel, Rongcheng Luo and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. NCOA5 Deficiency in Macrophages Provokes NASH and HCC.Cellular and molecular gastroenterology and hepatology · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mark Williams *Department of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA.
Xinhui Liu *Department of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA.
Yueqi ZhangDepartment of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA.
Jake ReskeDepartment of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA.
Devika BahalComparative Medicine and Integrative Biology Program, Michigan State University, East Lansing, Michigan, 48824, USA.
Trevor G GohlDepartment of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA.
Daniel HollernLineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, NC, 27599, USA.
Elliot EnsinkDepartment of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA.
Matti KiupelDepartment of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, Michigan, 48910, USA.
Rongcheng LuoCancer Center, Southern Medical University, Guangzhou, 510315, Guangdong, China.
Rupali DasDepartment of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA.
Hua XiaoDepartment of Physiology, Michigan State University, East Lansing, Michigan, 48824, USA. xiaoh@msu.edu.
Michigan State University · USSouthern Medical University · CNUniversity of North Carolina at Chapel Hill · US

Funding

Role of NCOA5 in hepatic steatosis and hepatocarcinogenesisR01CA188305 · NCI · MICHIGAN STATE UNIVERSITY · PI XIAO, HUA · 2015 to 2019
$1.7M
Integrative Training in the Pharmacological SciencesT32GM092715 · NIGMS · MICHIGAN STATE UNIVERSITY · PI NEUBIG, RICHARD R · 2011 to 2020
$1.5M
Roles of CD2 and 2B4 in invariant natural killer T (iNKT) cell functions.K22CA188149 · NCI · MICHIGAN STATE UNIVERSITY · PI DAS, RUPALI · 2015 to 2017
$542k
A molecular mechanism whereby metformin protects against liver cancerR21CA185021 · NCI · MICHIGAN STATE UNIVERSITY · PI XIAO, HUA · 2014 to 2015
$346k
NCI NIH HHS K22 CA188149NCI NIH HHS R01 CA188305NCI NIH HHS R21 CA185021NIGMS NIH HHS T32 GM092715
6 · The paper itself

Abstract

Prevention and treatment options for hepatocellular carcinoma (HCC) are presently limited, underscoring the necessity for further elucidating molecular mechanisms underlying HCC development and identifying new prevention and therapeutic targets. Here, we demonstrate a unique protumorigenic niche in the livers of Ncoa5

Indexed as

AnimalsCarcinogenesisCarcinoma, HepatocellularCD8-Positive T-LymphocytesCyclin-Dependent Kinase Inhibitor p21Disease Models, AnimalGene Expression Regulation, NeoplasticHumansLiverLiver NeoplasmsMacrophagesMiceMyeloid-Derived Suppressor CellsNuclear Receptor CoactivatorsTumor MicroenvironmentCdkn1a protein, mouseCyclin-Dependent Kinase Inhibitor p21NCOA5 protein, mouseNuclear Receptor Coactivators

Identifiers

PMID32203160
PMCPMC7210077
OpenAlexW3011441982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.